# Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

> **NCT01766739** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** GL-ONC1

## Key facts

- **NCT ID:** NCT01766739
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2024-10-24
- **Final completion:** 2024-10-24
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01766739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01766739, "Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01766739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*